BPC-157 + TB-500 calculator
A popular unregulated pairing of BPC-157 and TB-500 for tissue repair. Neither component is approved, and the combination is unstudied.
Also known as: Wolverine stack, BPC/TB4 blend
FDA status — not an approved drug Not FDA-approved. Both BPC-157 and the thymosin beta-4 fragment in TB-500 are in Category 2 of FDA's bulk drug substances list, and the combination has not been studied.
Schedule BPC-157 + TB-500 → Set your dosing schedule and get a phone notification when each dose is due. Free.
What BPC-157 + TB-500 is
BPC-157 with TB-500 is one of the most common peptide pairings, marketed for injury recovery. BPC-157 is a gastric-derived fragment; TB-500 relates to thymosin beta-4. Both have substantial animal data but no published randomized human trials, and the combination itself is unstudied.
Research depth: 2/5 Substantial animal data for each component, but no human trials of either alone or in combination. Human trials: None published. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How BPC-157 + TB-500 works
Each is proposed to promote tissue repair through overlapping but distinct routes — BPC-157 via VEGF-driven blood vessel growth and nitric oxide pathways, TB-500 via actin regulation and cell migration. The pairing is intended to be complementary, but no controlled study has tested whether the combination helps or how the two interact.
BPC-157 + TB-500 side effects
Commonly reported
- Injection-site irritation
- No systematic human safety data for either component or the combination
Serious — seek medical care
- Unknown long-term safety; the angiogenic mechanisms are a theoretical concern with undiagnosed cancer
- Prohibited in sport by WADA
- Unregulated products carry contamination and sterility risks
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 500 mcg dose is then 0.1 mL — about 10 units on a 100-unit insulin syringe, giving roughly 20 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable BPC-157 + TB-500 dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for BPC-157 + TB-500 run from 250 mcg to 1000 mcg. No established dosing exists for the combination — figures circulating reflect the individual components' community doses. There is no approved labeling for either.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use BPC-157 + TB-500 at all are decisions for a licensed clinician who knows your history.
Common questions
Why are BPC-157 and TB-500 combined?
They are paired on the theory that they support repair through different mechanisms. Neither has randomized human trial support, alone or together, and the combination is unregulated.
Is the combination safe?
Unknown. Neither component has systematic human safety data, and combining them has not been studied. Both raise the same theoretical angiogenesis concern.